Extrachromosomal DNA associates with poor survival across a broad spectrum of childhood solid tumors

Owen S. Chapman[1,2,3*], Sunita Sridhar[4,5*], Eugene Yui-Ching Chow[2], Rishaan Kenkre[2], Jonathan Kirkland[3], Aditi Dutta[6], Shanqing Wang[6], Riki Goto[1], Wenshu Zhang[3], Miguel Brown[7], Jens Luebeck[6], Hui Hui[3], Jessica Wang[2], Yan Yuen Lo[2,8], Elias Rodriguez-Fos[9], Shanzheng Wang[10,11,12,13], Konstantin Okonechnikov[10,11,12], David R. Ghasemi[10,14,15,16], Kristian W. Pajtler[10,11,12,17], Johannes Gojo[18], Anton G. Henssen[9], Marcel Kool[10], Vineet Bafna[6,19,20], Daisuke Kawauchi[1], Megan Paul[4,5], Kevin Yip[2], Jill P. Mesirov[19,21], Lukas Chavez[2,8,21,+]

1. Department of Neuro-oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;
2. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA;
3. Bioinformatics and Systems Biology Graduate Program, University of California San Diego, La Jolla, CA, USA;
4. Rady Children's Hospital San Diego, San Diego, CA, USA;
5. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA;
6. Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA;
7. Children's Hospital of Philadelphia, Philadelphia, PA, USA;
8. Rady Children's Institute for Genomic Medicine, Rady Children's Hospital and Healthcare Center, San Diego, CA, USA;
9. Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, Berlin, Germany;
10. Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany;
11. Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;
12. National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany;
13. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany;
14. Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;
15. Research Institute Children's Cancer Center, Hamburg, Germany;
16. Mildred Scheel Cancer Career Center HaTriCS[4], University Medical Center Hamburg-Eppendorf, Hamburg, Germany;
17. Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Germany;
18. Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria;
19. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA;
20. Halıcıoğlu Data Science Institute, University of California San Diego, La Jolla, CA, USA;
21. Department of Medicine, University of California San Diego, La Jolla, CA, USA;
+ Corresponding author
* Co-first authors

ABSTRACT

Circular extrachromosomal DNA (ecDNA) is a powerful driver of oncogene amplification and tumor evolution, yet its prevalence, composition, and clinical significance across pediatric cancers remains incompletely understood. Leveraging two major cloud-based genomic data repositories, we analyzed whole genome sequencing data from 3,630 tumor biosamples representing 2,967 children across 39 solid tumor types. ecDNA was identified in 9% of cases and was enriched in high-grade and clinically aggressive malignancies including ETMR, pediatric high-grade glioma, medulloblastoma, neuroblastoma, osteosarcoma and rhabdomyosarcoma. We catalogued 392 ecDNA sequences, revealing recurrent amplification of known oncogenes, diverse gene fusions, and oncogenic loci where recurrent ecDNA involvement underscores their emerging importance in pediatric tumors. Oncogenes amplified on ecDNA reached significantly higher copy number than chromosomal amplifications, and ecDNA was associated with significantly poorer 5-year survival independent of tumor type, age and sex. Longitudinal analyses demonstrated that ecDNA frequently arises, is lost, or undergoes structural remodeling during progression and recurrence, including acquisition or loss of oncogenes on the same circular element. Together, these findings define the landscape, clinical relevance, and evolutionary behavior of ecDNA across childhood cancers, highlight candidate drivers, and identify patient populations that may benefit from emerging ecDNA-targeted therapeutic strategies. An interactive resource is available at https://ccdi-ecdna.org/.

INTRODUCTION

Extrachromosomal DNA (ecDNA, also known as double minutes), are megabase-scale circular focal amplifications of genomic DNA which arise in many human cancers. ecDNA sequences generally contain an oncogene or other functional element conferring a selective fitness advantage, and lack a centromere, leading to unequal segregation during cell division and intra-tumoral heterogeneity. The potent combination of copy number heterogeneity and positive selection drives high-copy oncogenic amplification, rapid tumor evolution, and therapeutic resistance[1–3].

Paired-end whole genome sequencing has emerged as a cost-effective and efficient method to identify oncogenes and other sequences captured on ecDNA. While it was largely overlooked in early pediatric pancancer genomics studies[4,5], recent studies have described the prevalence of ecDNA in various adult and some childhood cancer types[6–10]. Recognizing that pediatric cancers have 14-fold lower somatic mutation frequency than adult cancers as well as unique drivers and amplifications[4,5], we have now comprehensively examined the frequency of ecDNA and its association with survival across a broad spectrum of primary and recurrent pediatric cancers.

RESULTS

Cloud genomic data repositories facilitate analysis of rare pediatric cancers.

To identify ecDNA in pediatric cancers, we analyzed whole genome sequencing (WGS) data available in two large pediatric cancer cloud genomics platforms: the Pediatric Brain Tumor Atlas (PBTA)[11] and St. Jude Cloud (SJC)[12] (**Figure 1**). In total, this retrospective cohort comprised 3,630 solid tumor biosamples from 2,967 patients with mean WGS coverage of 69x (±15) per sample. Clinical metadata, including histological diagnoses and patient survival

outcomes, were collated from both platforms (**Table 1; Supplementary Table 1**). For brain
tumors included in the PBTA, histological diagnoses were integrated with molecular tumor
type classifications derived from methylation analyses[13] of the same samples. We applied the
AmpliconArchitect (AA)[14] and AmpliconClassifier (AC)[15] algorithms to identify ecDNA
amplifications. Briefly, this pipeline performs joint analysis of genomic copy number and
structural variation in WGS data to construct a localized genome graph capturing the amplified
regions and identify ecDNA as genome cycles satisfying other heuristics including length and
copy number (**Methods**). In total, 392 ecDNA sequences were reported in 321 tumor
biosamples of 269 patients (9% of patients, **Supplementary Tables 1-3**). No association was
observed between presence of ecDNA and age at diagnosis ($R^2 = 0.005$, $p = 0.4$, Student's
t-test; **Supplementary Figure 1**) or sex ($\chi^2 = 1.3$, $p = 0.3$). As a quality control measure, we
estimated tumor purity and found no significant association with the identification of ecDNA
(likelihood ratio test, *p* = 0.15, *n* = 2133). Given that previous studies using similar methods
did not find ecDNA in adult hematologic malignances[6,8], we additionally sampled 10% of
available pediatric hematologic malignancies (*n* = 63, **Supplementary Table 4**). No ecDNA
was detected in those samples, and we therefore limited the scope of our investigation to solid
tumors.

ecDNA amplifies known and putative oncogenic sequences in pediatric solid tumors.

To identify oncogenic drivers amplified on ecDNA in pediatric solid tumors, we defined
recurrent genomic intervals as those amplified on ecDNA in at least three independent cases,
corresponding to a 99.9% confidence level against chance occurrence (**Supplementary Note
1**; **Supplementary Figure 2**). 109 distinct genomic intervals were recurrently amplified on
ecDNA across all pediatric cancers in this cohort (**Figure 2a**). To identify putative driver genes,
we annotated these genomic intervals with oncogenes listed in the COSMIC[16] and ONGene[17]
databases (**Supplementary Table 5**). Genomic intervals most frequently amplified on ecDNA
contained oncogenes *MYCN* (66 ecDNA amplifications observed in eight tumor types) or
CDK4 (22 ecDNA amplifications in six tumor types; **Figure 2b**). Five contiguous intervals
recurrently amplified on ecDNA contained clusters of three or more oncogenes: chr4q12
(*PDGFRA*, *KIT*, and *KDR*), chr8q24 (*TRIB1*, *MYC*, *PVT1*), chr11q22 (*YAP1*, *BIRC3*, *BIRC2*,
MMP12), chr12q13-14 (*GLI1*, *DDIT3*, *AGAP2*, *CDK4*), and chr12q15 (*IFNG*, *MDM2,
YEATS4*).

Accumulating evidence suggests that ecDNA enables greater oncogene copy number
amplification than chromosomal amplification[8]. To determine whether amplification by ecDNA
is of greater magnitude than other amplifications, we compared estimated copy number for
oncogenes amplified in cases on ecDNA and chromosomal amplifications (**Figure 2c**). Median
ecDNA copy number was greater for *PDGFRA*, *MYC*, *CCND2,* and chr17p11.2 compared to
chromosomal amplification of the same genes in other tumors (one-sided Mann-Whitney *U*
with Benjamini-Hochberg FDR correction, *q* < 0.05). Median ecDNA copy number was also
greater across all amplifications classified as ecDNA compared to chromosomal (*U* = 1e5; *p*
= 2e-61; **Figure 2d**), suggesting that oncogenic amplification occurs at greater magnitude in
ecDNA than in chromosomal amplifications in pediatric cancers.

82 genomic intervals recurrently amplified on ecDNA contained no known oncogene. These
were relatively short (mean 181kbp, standard deviation 301kbp); however, 38 of these
contained uninterrupted gene sequences, nominating 81 protein-coding genes and 235 long
noncoding RNAs (lncRNA) as candidates under positive selection (**Supplementary Table 6**).
These other recurrently amplified genes exhibited median ecDNA copy numbers comparable

to known oncogenes (two-sided Mann-Whitney test; U = 138; p = 0.23; **Supplementary**
Figure 3). Several recurrently amplified genomic intervals were exclusively co-amplified on
ecDNA with known oncogenes on recombinant DNA sequences, suggesting that possible
positive selection may be context-dependent[18]. To nominate *bona fide* oncogenic candidates,
we therefore further asked which genomic intervals were recurrently amplified on ecDNA yet
lacked any co-amplified known oncogenes. As a result, we identified five genomic intervals
that fulfilled these criteria, each containing genes with prior evidence supporting tumorigenic
roles. For example, a peritelomeric recurrently amplified locus at chromosome 1q amplified
the full gene sequences of *AKT3* and *ZBTB18* in two high-grade gliomas and a
rhabdomyosarcoma (**Supplementary Figure 4**). In mouse models, amplification and
overexpression of the paralogous gene *Akt3* promotes malignant glioma progression[19,20],
supporting a functional role for this gene locus in some human pediatric tumors. The other
examples contain the DNA replication initiation cofactor *TRPS1*[21], neurodevelopmental factor
NTN1[22,23], the *C19MC* microRNA cluster frequently amplified in embryonal tumors with
multilayered rosettes (ETMR)[24], and the recombination hotspot at chr17p11.2-12 in
osteosarcomas[25] and medulloblastomas[26].

ecDNA in aggressive childhood central nervous system tumors

We observed ecDNA most frequently in embryonal tumors with multilayered rosettes (4/9,
44%), pediatric high-grade gliomas (78/391, 20%), and medulloblastomas (55/347, 16%); and
rarely in pineal tumors (1/28, 4%), choroid plexus tumors (1/56; 2%), craniopharyngiomas
(1/101, 1%), ependymomas (3/239, 1%), glioneuronal tumors (1/192, 0.5%), and low-grade
gliomas (1/616, 0.2%) (**Figure 3a**).

Embryonal tumors with multilayered rosettes (ETMR) have poor outcomes and most are
characterized by amplification of a microRNA cluster on chromosome 19 (*C19MC*) including
fusion of the *TTYH1* gene[27]. Of 9 ETMR cases, 4 had *TTYH1*::*C19MC* amplification, all
extrachromosomal, suggesting that *C19MC* amplification in ETMR tumors may occur
predominantly on ecDNA.

To evaluate this hypothesis, we examined a validation cohort of 30 additional ETMR tumors
(**Supplementary Table 7**). Copy number estimation from bulk WGS indicated *C19MC*
amplification (CN > 4.5) in 18 cases and moderate gain (2.5 < CN < 4.5) in an additional 8
cases. Using default analysis parameters, 16 of 18 amplifications were classified as ecDNA
and 2 as chromosomal amplifications. To improve detection sensitivity, we reanalyzed the 8
cases with moderate *C19MC* gain (**Methods**) and identified an additional 5 ecDNA and 1
chromosomal amplicon, indicating that ecDNA detection sensitivity may be limited for
amplicons with low copy burden.

Overall, ecDNA containing *TTYH1*::*C19MC* fusion was detected in 21 of 30 cases in the
validation cohort (70%). Chromosomal amplicons containing the fusion were detected in an
additional 3 cases (10%). The fraction of *C19MC* amplicons classified as extrachromosomal
in the validation set (21/24) did not differ significantly from the discovery set (4/4; p = 1, Fisher
exact test), substantiating the high prevalence of extrachromosomal *C19MC* amplification in
a larger ETMR cohort. Moreover, ecDNA amplifications of *KANSL1* and *YAP1* were found in
non-*C19MC*-amplified tumors in the validation set, suggesting possible alternative driver
amplifications of non-*C19MC*-amplified ETMR.

The clinical outcomes of pediatric high-grade glioma (pHGG) patients differ across
molecular subgroups marked by genetic mutations to the histone H3 or isocitrate
dehydrogenase (*IDH*) genes[28]. pHGG with H3 mutations are further stratified into those

mutated at lysine 27 (H3K27) and at glycine 34 (H3G34). Among 380 pHGG tumors, 77 had ecDNA (20%), including 29 of 103 with wild-type H3 (28%), 29 of 132 H3K27-mutant (22%), 2 of 16 H3G34-mutant (13%), and 4 of 10 with *IDH* mutation (40%). Known oncogenes[28–30] recurrently amplified on ecDNA included *PDGFRA* (n = 14), *CDK4* (12), *MYCN, KIT* (10), *MET* (8), *EGFR* (6), *GLI1* (5), *CDK6, MYC, MDM2* (4), *ID2, CCND2,* and *PLAGL2* (3).

In a previous analysis of 481 medulloblastoma (MBL) tumors, we showed significant associations between ecDNA status and survival across all MBL tumors and in each molecular subgroup[7]. 168 MBL tumors were reanalyzed herein alongside 174 new cases. ecDNA was detected in 16%, modestly lower than that reported previously (18%), which may be attributed to differences in the patient cohorts and analytical methods (**Supplementary Note 2**).

The low frequency of ecDNA detected in choroid plexus tumors, pineal tumors, craniopharyngiomas, ependymomas, CNS glioneuronal tumors, and low-grade gliomas (**Supplementary Note 3**) prompts the question of whether ecDNA amplifications are incidental findings or characteristic to well defined rare molecular subtypes. For pineal tumors and ependymomas with available DNA methylation-based classifications, ecDNA amplifications were indeed limited to the recently-described rare molecular subtypes *MYC*-amplified pineoblastoma[31] and *MYCN*-amplified spinal ependymoma[32,33] respectively. To validate these findings, we obtained new WGS data from 3 *MYCN*-amplified spinal ependymomas. Amplicon analysis identifies ecDNA in each, suggesting that amplification of *MYCN* in this molecular subtype may commonly be driven by ecDNA. Overall, although further studies of larger tumor-specific cohorts are needed, these observations suggest that ecDNA amplification may be limited to some ultra-rare and highly aggressive subtypes and are otherwise largely absent in these tumor types.

ecDNA in pediatric extracranial solid tumors

ecDNA has been previously described in various extracranial pediatric solid tumors, most extensively in neuroblastoma[9,18], and in case reports and cell lines of retinoblastoma[34,35], rhabdomyosarcoma[29,36–41], and osteosarcoma[42]. We identify patient tumors with ecDNA for each of these extracranial tumor types, as well as in adrenocortical carcinomas, Wilms tumors, germ cell tumors, malignant peripheral nerve sheath tumors, and other rare sarcomas (**Figure 3b**).

Consistent with previous analyses[9,10], we estimate the prevalence of ecDNA in neuroblastoma at 40/159 (25%). Most tumors with ecDNA amplified *MYCN* (35/40, 88%). Of 5 remaining ecDNA(+) tumors not amplifying *MYCN*, two had ecDNA amplifications of *TERT*, and 3 had low-copy ecDNA containing no known oncogenic sequences.

Although *RB1* gene inactivation is the canonical driver of retinoblastoma, other mechanisms including oncogenic amplification are believed to contribute to tumorigenesis in some cases[43]. ecDNA has previously been described in retinoblastoma cell lines and patient tumors and is particularly associated with *MYCN* amplification[35]. In this cohort, six of 44 (14%) retinoblastoma cases had ecDNA, two of which amplified *MYCN*. A further two ecDNA amplifications disrupted the *RB1* gene to form gene fusions, with lipoma *HMGIC* fusion partner gene family member *LHFPL6* (*RB1-LHFPL6)* or with the *TPTE2P2* pseudogene (*RB1-TPTE2P2)*. In the remaining two tumors, no canonical oncogenes were identified, suggesting that these highly amplified ecDNA sequences may contain previously unknown oncogenic drivers for this tumor type.

Osteosarcomas are frequently characterized by high genomic instability with some genomic regions frequently involved in copy number gain events[44,45]. Prognosis is poor with few advances in standard treatment for the past 30 years[46]. ecDNA was detected in 36 of 70 cases (51%). We identified recurrent ecDNA amplifications at chromosomes 6p21 (*FOXP4*[47], 4 cases), 12q13 (*GLI1*, *CDK4*, 6 cases), 17p11.2-p12[48,49] (11 cases), and 19q12 (*CCNE1*, 4 cases). 3 tumors had more than one of these recurrently amplified regions on distinct ecDNA sequences.

Double minutes have been described in case reports of rhabdomyosarcoma (RMS) as early as 1971[36,37,39,50,51]. Amplifications of *MYCN*[52] and fusion oncogenes between *FOXO1* and *PAX3* or *PAX7*[53] have been previously identified as prognostic indicators. ecDNA was detected in 16 of 49 RMS cases (33%). Amplified oncogenes included *PAX7-FOXO1* fusion, *MDM2* (*n* = 2), *MYCN*, *FGFR1*, *NCOA1-PAX3* fusion, and *NSD3* (*n* = 1). One tumor harbored ecDNA where none of the amplified genes were annotated in the two queried oncogene databases; however, we suggest the cell cycle regulators *CDK11A* and *CDK11B* as likely oncogenic candidates.

In contrast to a previous pan-cancer study[6], we did not observe ecDNA in any of 53 pediatric Ewing sarcomas. On further investigation, we noted that tumors previously annotated as Ewing sarcomas have been subsequently reannotated as osteosarcomas (**Supplementary Table 8**), explaining the discrepancy and suggesting that ecDNA does not play a major role in oncogenesis of pediatric Ewing sarcomas.

We also report ecDNA sequences in 4 adrenocortical carcinomas, 4 Wilms tumors, 2 germ cell tumors, 2 malignant peripheral nerve sheath tumors, 2 hepatoblastomas, one pediatric melanoma, and one hepatic focal nodular hyperplasia. These cases are described in **Supplementary Note 4**.

Tumors with ecDNA, chromosomal, or no focal amplification have distinct distributions of somatic small variants.

Somatic variant calling and annotation were performed on paired blood/tumor WGS data from both the SJ and CBTN datasets to assess whether the distribution of somatic mutation (single nucleotide variants (SNVs) and short indels < 50bp) differs in ecDNA-amplified tumors. For this analysis, we defined likely pathogenic (*LP*) somatic variants as somatic mutations of cancer-related genes which altered the protein sequence and were predicted to be functional (**Methods**). Aggregating *LP* mutations at the gene level, we first compared amplified to nonamplified tumors (**Supplementary Figure 5a**). Mutations of *BRAF* and *CTNNB1* were depleted in tumors with amplification, likely reflecting enrichment of *BRAF* and *CTNNB1* mutations in low-grade gliomas, glioneuronal tumors, and *WNT* subgroup medulloblastomas in which focal amplification is rare. Amplified tumors were enriched for mutation of *TP53*, *H3-3A*, *KNL1*, *PDGFRA*, *PABPC1*, *AURKA*, *STAG2*, and *KNSTRN* (*n* = 7071 *LP* somatic variants across 1798 solid tumors; χ^2 tests with FDR correction, *q* < 0.10; **Supplementary Table 9**). Notably, *KNL1*, *AURKA, STAG2* and *KNSTRN* are required for proper chromosomal pairing and segregation during mitosis, suggesting a plausible link between defects in this process and the presence of focal amplification in pediatric solid tumors. Due to the large hypothesis space, this analysis was underpowered to examine differences between extrachromosomally and chromosomally amplified tumors, but we note that alterations to *GNAS* were nominally depleted in tumors with ecDNA vs. amplified tumors without ecDNA (**Supplementary Figure 5b**). In an analysis of germline variation using similar methods across a subset of CNS tumors,

pathogenic germline variants of *TP53* (Li-Fraumeni Syndrome, LFS) were associated with
focal amplification overall but did not show specific enrichment for ecDNA (**Supplementary**
Note 5).

We next asked whether tumor mutation burden (TMB) or likely pathogenic somatic mutation
burden (LPTMB) differed across the ecDNA, chromosomally amplified, or nonamplified
tumors. To test this, we fitted logistic regressions on tumor type, age at diagnosis, sex and
batch (SJ or CBTN). No independent effect of TMB (Wald test; $p = 0.74$; $n = 1749$) or LPTMB
($p = 0.51$) was observed in amplified vs. nonamplified tumors (**Supplementary Figure 5c**);
however, within the amplified tumor subset, ecDNA(+) tumors had lower LPTMB than
chromosomally amplified ($p = 0.007$; $n = 232$), accounting for independent effects of the above
covariates (**Supplementary Figure 5d**). These results indicate that age and tumor type are
likely the strongest determinants of overall tumor mutation burden, but that tumors with
extrachromosomal amplification have significantly lower LPTMB than tumors with
chromosomal amplifications only.

ecDNA is associated with poor survival in pediatric cancers.

To investigate whether ecDNA in pediatric cancers is associated with worse clinical
outcome, we performed Kaplan-Meier regression on overall survival data available for 1820
patients (**Supplementary Table 1**). Here, we stratified patients into those whose tumors had
ecDNA ($n = 216$), chromosomal amplification only ($n = 225$), or no focal amplification ($n =$
1452). Kaplan-Meier regression indicated that patients with ecDNA(+) tumors had significantly
worse outcomes than patients with tumors containing no amplification (log-rank test, adjusted
$p < 2e\text{-}16$) and patients with chromosomal amplifications (adjusted $p = 7e\text{-}6$) (**Figure 4a**). To
estimate the magnitude of the association between ecDNA and survival, we performed Cox
regression of sex, age at diagnosis, tumor type, and amplification type (ecDNA, chromosomal,
or no amplification). Controlling for available covariates, ecDNA detected in a patient tumor
conferred twofold risk of death within 5 years relative to tumors without amplification (hazard
ratio 2.1, $p = 5e\text{-}9$, Wald test), and one-and-a-half-fold risk relative to tumors with
chromosomal amplification but no ecDNA (HR 1.5, $p = 0.02$, **Figure 4b**).

Because childhood cancers are rare and highly diverse, survival analyses could not be
performed robustly for every tumor type due to limited patient numbers within each category.
To address this limitation, we integrated our cohort with previously published whole genome
sequencing datasets from studies of medulloblastoma[7], neuroblastoma[10], and pediatric high-
grade glioma[54]. This approach enabled us to investigate more thoroughly the association
between ecDNA and patient outcomes within each of these three tumor types.

Joint modelling of focal amplification, ecDNA, molecular subgroup, and other clinical
variables across 445 MBL tumors suggests that ecDNA (HR 2.8, $p = 6e\text{-}4$), rather than focal
amplification of any kind (HR 0.9, $p = 0.71$) is a stronger predictor of 5-year survival
(**Supplementary Figure 6a-b**). Similarly, survival regressions across 175 NBL tumors
estimate poorer 5-year overall survival for ecDNA(+) tumors accounting for chromosomal
amplifications (KM: $p = 0.042$, BH-adjusted log-rank test, **Supplementary Figure 6c**; Cox: HR
= 2.8, $p = 0.048$, **Supplementary Figure 6d**), consistent with a previous report stratifying NBL
tumors with focal amplification into high-risk with ecDNA amplification of *MYCN* vs.
intermediate-risk with chromosomal amplification elsewhere in the genome[10].

Myc family genes *MYC* and *MYCN* are major drivers of aggressive medulloblastoma[55] and
neuroblastoma[9,10]. We next investigated whether clinical outcomes may differ by the context
of Myc family oncogene amplification, i.e. ecDNA or chromosomal. Across both cancer types,
MYC and *MYCN* were amplified predominantly on ecDNA (MBL: 34/40, 85%; NBL: 27/31,

87%), leaving few chromosomally amplified cases as internal comparators. As expected,
adjusting for Myc family gene amplification reduced the estimated hazard of ecDNA for both
medulloblastoma (HR = 1.7, *p* = 0.14; **Supplementary Figure 7a-b**), and neuroblastoma (HR
= 1.2, *p* = 0.78; **Supplementary Figure 7c-d**). We can therefore confirm that amplification of
Myc family genes in these tumors in their predominantly extrachromosomal form carries an
exceptionally poor prognosis, consistent with previous reports[10,55]; although the scarcity of
chromosomally amplified *MYC*(*N*) tumors limits assessment of whether extrachromosomal
Myc family amplification exerts further prognostic influence compared to chromosomal.

Molecular determinants of prognosis in pediatric high-grade gliomas include pathogenic
mutations of histone 3 (H3), *IDH*, and *TP53* genes as well as focal amplification of diverse
oncogenes. It has been previously shown that complex structural variants are associated with
poorer overall survival of pHGG patients, where *TP53* loss and ecDNA were enriched in the
complex-SV group[54]. Combining that cohort with pHGG tumors from our pancancer cohort,
we confirmed that the strongest predictor of outcome was H3K27M mutation, which
distinguishes high-risk diffuse midline gliomas (DMG) with universally poor prognoses
(**Supplementary Figure 8a-b**). Further stratification by amplification status showed that the
presence of chromosomal or extrachromosomal amplification was nominally but non-
significantly associated with poorer survival within 5 years of diagnosis (**Supplementary
Figure 8c**). Given the exceptionally poor outcomes associated with H3K27 alteration, we
hypothesized that the presence of H3K27M mutation may supersede the prognostic utility of
ecDNA in this tumor subtype. In a revised hierarchical model stratified by H3K27 alteration,
we estimated that ecDNA is a prognostic indicator specifically in H3K27 wild-type tumors (HR
= 1.81; *p* = 0.02); however, the estimated additional hazard of ecDNA in H3K27-altered tumors
was nonsignificant and near-zero (HR = 1.2; *p* = 0.58; **Supplementary Figure 8d**). These
findings indicate a context-dependent role for ecDNA in pHGG prognosis, where it is predictive
of worse overall survival except in H3K27-altered tumors.

ecDNA evolves during progression and recurrence of pediatric cancers.

Recognizing that ecDNA may contribute to tumor evolution and treatment resistance, we
next compared its prevalence in primary versus relapsed tumors and tracked its dynamics in
longitudinal primary-relapse pairs.

For this analysis, we aggregated progression, recurrence, relapse, and metastasis into one
category of secondary samples. Secondary malignancies and autopsy samples were
excluded, as were tumor types without focal amplification. ecDNA was modestly but
significantly more frequent in secondary (57 of 519, 11%) than primary tumors (202 of 2448,
8%), controlling for tumor type (**Figure 5a**; stratified permutation test, *p* = 0.002). Tumors with
chromosomal amplifications alone were not enriched in secondary compared to primary
tumors (**Figure 5b**; *p* = 0.45).

To characterize patterns of ecDNA evolution, we collated 29 longitudinal cases where
ecDNA was detected in at least one of sequential tumor samples of the same patient
(**Supplementary Table 10**). Here, we included an ecDNA(+) medulloblastoma patient tumor
diagnosed at Rady Children's Hospital, San Diego[7] and for which we generated new WGS
data from the relapse. In these 29 longitudinal cases, we observed 39 distinct ecDNA
sequences. Of these, 13 ecDNA arose *de novo* compared to earlier tumor samples (gain) and
10 ecDNA were not detected in a later tumor sample (loss). Two chromosomal amplifications
were identified as ecDNA in a later tumor sample (circularization). We do not observe
examples of ecDNA amplification later reclassified as non-ecDNA chromosomal amplification.
For extrachromosomal amplifications detected in the same patient at more than one timepoint,
we asked whether the ecDNA had undergone structural variation in the interim, using a

heuristic similarity metric incorporating Jaccard similarities of the amplified sequences and
breakpoints (**Methods**). Five such ecDNA amplicons were conserved ($S > 0.7$) whereas the
other nine showed structural evolution, including examples where a new oncogene was added
(**Figure 5c**) or lost (**Supplementary Figure 9**) in the later tumor. For example, in a pHGG
patient (SJHGG019), we observe the oncogenes *EGFR* and *CDK6*, both coded on chr7, co-
amplified on the same ecDNA. The ecDNA observed in the relapse tumor of the same patient
contained *MYC*, coded on chr8, as a third oncogene on the same ecDNA together with *EGFR*
and *CDK6* (**Figure 5c**). Overall, these results suggest clonal tumor dynamics in which ecDNA
may emerge, mutate, remain conserved, or be lost during disease progression.

Patient tumors with more than one ecDNA sequence showed longitudinal variability in the
combinations of ecDNA sequences detected. For example, we previously observed two
distinct ecDNAs, originating from chromosomes 1 and 7 respectively, present in a primary
SHH medulloblastoma tumor[7]. In WGS data from the recurrent tumor of the same patient, we
observe conservation of the ecDNA amplification originating from chromosome 1, whereas
the ecDNA amplification originating from chromosome 7 was no longer detected in the relapse
tumor. This and other examples (**Figure 5d**) highlight that multiple distinct ecDNA sequences
provide tumors with flexibility to amplify different oncogenes and oncogene combinations
during disease progression.

DISCUSSION

By leveraging childhood cancer data cloud repositories with whole-genome sequencing
data, we estimate frequencies of circular extrachromosomal amplification across a wide
spectrum of childhood cancer types. Where grading of the tumor was incorporated into the
histological or molecular diagnosis, the higher-grade diagnoses (pediatric high-grade glioma,
choroid plexus carcinoma, malignant peripheral nerve sheath tumor, and pineoblastoma) had
greater incidence of ecDNA than the lower-grade diagnosis (pediatric low-grade glioma,
choroid plexus papilloma, neurofibroma, and low-grade pineal tumors), suggesting that
ecDNA may be more frequent in pediatric tumors with high-grade histology across tissue
origins. Notable high-grade tumor types in which we did not observe ecDNA are defined by
well described oncogenic mutations, such as biallelic loss of *SMARCB1/SMARCA4* in atypical
teratoid rhabdoid tumors (ATRT)[56], *EWSR1*::*FLI1* (also commonly *EWS*/*FLI*) in Ewing
sarcoma, or *ZFTA*[56] gene fusions in supratentorial ependymoma. Consistent with a
"Goldilocks principle", excessive expression of *EWSR1*::*FLI1* is deleterious in Ewing
sarcoma[57], rendering high-copy amplification on ecDNA disadvantageous. A similar
phenomenon may constrain *ZFTA* fusions in ependymoma, where ecDNA amplification would
push fusion oncofactor activity beyond a tolerable range[58]. By contrast, solid tumor types
where drivers benefit from gene dosage escalation more frequently contain ecDNA. Although
we did not comprehensively analyze hematological cancers, a pediatric case report[59] and a
recent retrospective analysis of adult leukemias[60] recommend this area for further
investigation.

Patients with tumors containing ecDNA had significantly poorer survival compared to those
with chromosomal amplification and those without amplification, controlling for sex, age and
tumor type. This finding suggests that both focal amplification and extrachromosomal
amplification have nonredundant prognostic value in pediatric cancers. The majority of
ecDNA(+) tumors contained at least one well described oncogene, such as *MYC, MYCN,*
CDK4, and others. In some tumors, multiple oncogenes were amplified on one or multiple
ecDNA sequences. Other ecDNA amplifications contained genes not annotated in the

COSMIC[16] and ONGene[17] oncogene databases but with plausible oncogenic roles, including
AKT3, NTN1, and others. In rhabdomyosarcoma and retinoblastoma, we found recurrent gene
fusions on ecDNA. The potential oncogenic roles of still many other ecDNA-amplified
sequences without known oncogenes are less clear. For example, relatively little is known of
the role of chr17p11.2 amplification, the most frequent ecDNA amplification in osteosarcomas.
Intriguingly, this locus is a recombination hotspot in medulloblastoma[26] and in some
nonmalignant genetic disorders[61,62]. Given the current poor prognosis of osteosarcomas and
the need for more effective treatment protocols, further analysis of this and other recurrently
amplified loci are warranted to identify novel oncogenic drivers and treatment targets.

Across a set of paired primary/secondary cases, we observed various structural
rearrangements of ecDNA sequences. This adds to accumulating evidence[2,7,63] that ecDNA
facilitates tumor evolution in response to therapeutic or other selective pressures. Secondary
tumors contained ecDNA more frequently than primary tumors, controlling for tumor type,
consistent with a previous analysis of adult tumors[63]. Due to limited treatment information
available for this cohort, the role of extrachromosomal DNA evolution in the emergence of
drug resistance under standard-of-care treatment including chemo- and radiotherapy remains
to be further elucidated and functionally tested in pediatric solid tumor models.

Overall tumor mutation burden (TMB) was not associated with amplification or with ecDNA;
however, ecDNA-amplified tumors had fewer somatic simple variants with predicted functional
consequence targeting cancer genes than chromosomally amplified tumors. Speculatively, a
possible explanation for this observation is that ecDNA may be sufficient to drive tumor growth
with fewer secondary driver mutations. Focal amplification was specifically associated with
somatic alterations to DNA damage response gene *TP53* and to chromosomal pairing and
segregation components *KNL1*, *AURKA*, *STAG2*, and *KNSTRN*; however, no specific
association was observed for ecDNA vs. chromosomal amplification. Should this observation
prove generalizable, a possible explanation is that mechanisms for ecDNA generation
associated with *TP53* inactivation such as chromothripsis[64] may be at least as likely to
generate chromosomal forms of focal amplification; or that other p53-independent
mechanisms of ecDNA generation may yet be found. Future work will be required to
substantiate and functionally validate the predictors of ecDNA and their potential underlying
mechanisms.

Identification of ecDNA in patient tumors holds promise in prognostication and targeted
treatment. Although the spectrum of known and putative oncogenic sequences on ecDNA is
diverse and tissue-specific, there is some hope that patients with ecDNA(+) tumors may
benefit from future therapies targeting a common vulnerability. For example, a recent study
demonstrated that combination treatment of an ecDNA(+) gastric tumor using inhibitors
against the ecDNA-amplified *FGFR* oncogene and a CHK1 inhibitor enhances transcription-
replication conflict and prevents ecDNA-mediated acquired resistance that otherwise
develops under FGFR inhibition alone[65]. Our results show that this approach may also be
applicable to some high-risk pediatric tumors. For example, we recently reported preliminary
clinical real-world experience using avapritinib, a next-generation tyrosine kinase inhibitor, in
pediatric and young adult patients with recurrent/refractory PDGFRA-altered HGG[66].
Avapritinib was well tolerated and led to initial radiographic responses in 3 out of 7 cases. In
one patient, *de novo EGFR* amplification was observed in a metastatic lesion that progressed
during treatment, indicating oncogene switching as a possible resistance mechanism. A
promising avenue for future investigation is whether combination therapy with an ecDNA-
targeting treatment may prevent ecDNA-mediated resistance. ecDNA may also hold promise

for detection via liquid biopsy as genes identified on ecDNA including *MYCN*[67], *MYC*[68], and
C19MC[69] are currently under investigation as liquid biomarkers.

Overall, this study highlights the spectrum of pediatric cancer patients with poor prognosis
who may benefit from ecDNA-directed therapies. To facilitate future discovery, the dataset is
available through interactive web portals at https://ccdi-ecdna.org/ and
https://ampliconrepository.org/project/PedPanCan.

 TABLES AND FIGURES

	N = 2,967[1]
Sex	
Female	1,308 (44%)
Male	1,627 (55%)
Not Reported	32 (1.1%)
Age at Diagnosis (years)	
<1	166 (5.8%)
1–4	741 (26%)
5–9	733 (25%)
10–14	693 (24%)
15–18	380 (13%)
19–40	164 (5.7%)
Race	
White	1,904 (64%)
Black Or African American	321 (11%)
Asian	93 (3.1%)
Multiracial	76 (2.6%)
American Indian Or Alaska Native	10 (0.3%)
Native Hawaiian Or Other Pacific Islander	7 (0.2%)
Other	406 (14%)
Not Reported	150 (5.1%)
Ethnicity	
Hispanic Or Latino	310 (10%)
Not Hispanic Or Latino	2,301 (78%)
Not Reported	356 (12%)

466
467

468
469 **Figure 1: Analysis of ecDNA in pediatric cancers using cloud computing.** (**a**) Whole
470 genome sequencing (WGS) data of solid tumors was analyzed in two cancer genome cloud
471 repositories. ecDNA and other amplifications were identified and annotated with clinical
472 information for downstream analysis. (**b**) Tumor biosample distribution by tumor type.
473 Abbreviations are expanded in **Supplementary Table 12**.
474

Figure 2: Genomic distribution and copy number of recurrent ecDNA amplifications in
pediatric tumors. (**a**) Histogram of ecDNA amplifications in pediatric tumors across the
reference human genome. 106 contiguous genomic loci were recurrently ($n \geq 3$) amplified
containing 49 different oncogenes. Selected genes are shown: black, oncogenes listed in the
COSMIC or ONGene databases; blue, other recurrently amplified genes. (**b**) Amplifications in
(**a**) by tumor type. Heatmap indicates the number of cases with ecDNA amplification of a given
gene in that tumor type. Right barplot indicates the number of ecDNA sequences amplifying
any of the indicated genes for each cancer type. Top barplot indicates the number of ecDNA
sequences amplifying the indicated gene across all tumor types. (**c**) Estimated copy number
of extrachromosomal and chromosomal amplifications of selected oncogenes. ** $q < 0.005$; *
$q < 0.05$; ns, $q \geq 0.05$; one-sided Mann-Whitney U test with Benjamini-Hochberg FDR
correction. (**d**) Estimated copy number of amplicons containing at least 1 gene. Legend and
statistical tests are the same as in (c). HGG, high-grade glioma; MBL, medulloblastoma; NBL,
neuroblastoma; OS, osteosarcoma; RMS, rhabdomyosarcoma; ETMR, embryonal tumor with
multilayered rosettes; WT, Wilms tumor; EMBT, miscellaneous embryonal brain tumors; GCT,
germ cell tumors; MST, metastatic secondary tumors; RBL, retinoblastoma; CPG,
craniopharyngioma; EPN, ependymoma; MEL, melanoma; PINT, pineal tumors; PNST,
peripheral nerve sheath tumors; SARC, other miscellaneous sarcomas.

Figure 3: Prevalence of ecDNA across pediatric tumor types. Across 39 pediatric tumor categories, we report ecDNA in 23. Pie chart area is proportional to the log of the sample size for a given tumor. *Includes additional samples from an external validation set analyzed with different methods (see **Methods**).

Figure 4: Overall survival of pediatric patients with ecDNA(+) tumors. Sample was limited to tumor types with at least 5 cases, at least 1 ecDNA(+) sample, and at least 1 clinical event. (**a**) Patients with ecDNA(+) tumors have significantly worse outcomes than patients with tumors containing no amplification (adjusted *p* < 2e-16) or patients with chromosomal amplifications (adjusted *p* = 7e-6; log-rank test with Benjamini-Hochberg correction). (**b**) Cox regression indicates twofold risk of death for patients with ecDNA compared those without amplifications (hazard ratio 2.1, *n* = 1836, *p* = 5e-9) and one-and-a-half-fold relative to patients with chromosomal amplifications only (HR 1.5, *p* = 0.02). ***q<0.001; **q<0.01; *q<0.05; ns, *q*≥0.05.

Figure 5: Sequence evolution of ecDNA during disease progression. (a-b) Proportion of (**a**) tumors with ecDNA and (**b**) tumors with chromosomal amplification only, by tumor type. *p*-values derived from permutation tests stratified by tumor type. (**c**) 39 ecDNA sequences were observed longitudinally in 29 tumors. We classified these based on ecDNA sequence over time: conservation (no change), recombination (sequence addition or loss to an extant ecDNA), loss (no amplification observed in the latter sample), gain (no amplification in the earlier sample), or circularization (chromosomal amplification at the same locus in the earlier sample). No examples were observed of linearization (chromosomal amplification at the same locus in the later sample). (**d**) Multiple ecDNA sequences were observed longitudinally in 6 tumors. Amplified oncogenes are annotated. EPN, ependymoma; ETMR, embryonal tumor with multilayered rosettes; HGG, high-grade glioma; MBL, medulloblastoma; RMS, rhabdomyosarcoma; OS, osteosarcoma.

SUPPLEMENTARY FIGURES

Supplementary Figure 1: Ordinary least squares regression of focal amplifications in patient tumors on age at diagnosis. (**a**) Ages at diagnosis were binned to 0.1-year resolution, and class proportions (ecDNA, chromosomal amplification, or no amplification) were computed for each age group. To reduce sampling noise, a centered 1-year rolling average was applied to the age-wise amplicon class distributions. (**b**) Distribution of sample counts by age. (**c-e**) Ordinary least squares linear regressions for proportion of tumors with chromosomal amplification ($R^2 = 2\mathrm{e} - 4$, $p = 0.84$, Student's *t*-test), ecDNA ($R^2 = 0.005$, $p = 0.38$), or no amplification ($R^2 = 0.003$, $p = 0.41$).

Supplementary Figure 2: Expected and observed distributions of ecDNA across the human reference genome. A null hypothesis H_0 in which ecDNA is uniformly and randomly distributed across the genome was modelled explicitly as a Poisson distribution with rate parameter λ proportional to the number and average length of ecDNA sequences (red circles) and experimentally by shuffling the locations of ecDNA across the genome (blue bars). 99.9% of the probability mass of H_0 falls within the range $0 \leq n < 3$, such that the chosen threshold n ≥ 3 corresponds to a p-value threshold of p=0.001. By contrast, the observed distribution of ecDNA (H_1, orange bars) was concentrated at some genomic regions, indicating a nonrandom distribution of ecDNA in pediatric cancer genomes. PMF, probability mass function.

568 **Supplementary Figure 3: Copy number of genes recurrentlu amplified on ecDNA.** (**a**) Estimated
569 copy number of each amplification for genes of interest indicated in **Figure 2**. (**b**) Medians of gene copy
570 numbers in (**a**); two-sided Mann-Whitney U test; $U = 138$; $p = 0.23$. Medians of *PVT1*, *BIRC2*, *BIRC3*
571 and *DDIT3* were excluded for violations of the indpendence assumption.
572

573
574
Supplementary Figure 4: A recurrently ecDNA-amplified locus contains putative
oncogene *AKT3*. (**a**) Panel reproduced from **Fig. 2a**. Chromosomal co-ordinates of ecDNA
amplifications were stacked to generate a histogram of ecDNA amplifications across the
genome. Selected recurrently amplified ($n \geq 3$) genes of interest are highlighted. (**b**)
Histogram data from (a) zoomed in to show a 5Mbp peritelomeric portion of chr1 containing
the *AKT3* locus. The consensus genomic region amplified in all 3 tumors, or maximally
amplified region, contains 2 complete protein-coding gene loci: *AKT3* and *ZBTB18*. (**c**)
Circular sequence assemblies of the ecDNA sequences containing the full-length *AKT3* locus.
Known and putative oncogenes *AKT3* and *MYCL* are highlighted in red.
584

585
Supplementary Figure 5: Tumor mutation burden of ecDNA(+) and chromosomally
amplified tumors. (**a**-**b**) Associations of "likely pathogenic" somatic simple variants, defined
as simple variants with predicted functional consequence targeting cancer-related genes, in
(**a**) amplified vs. nonamplified and (**b**) ecDNA(+) vs. chromosomally amplified pediatric tumors
(n = 1798). Genes are labelled in which pass the q < 0.10 significance threshold (χ^2 test with
BH correction) indicated by the horizontal bar. (**c**-**d**) Maximum likelihood logistic regression
models of (**c**) amplified vs. nonamplified (n = 1749) and (**d**) ecDNA vs. chromosomal
amplification (n = 232) on age at diagnosis, batch, TMB, LPTMB, tumor type and sex.
Reference tumor type is low-grade glioma, LGG.
595

596
Supplementary Figure 6: Survival of medulloblastoma and neuroblastoma tumors w.r.t.
ecDNA. (**a**) Survival of 491 MBL tumors stratified by presence of chromosomal or
extrachromosomal amplification. (**b**) Cox proportional hazards regression of 445 MBL tumors
from (**a**) with complete metadata for molecular subgroup and clinical parameters. (**c**) Survival
of 175 NBL tumors stratified by chromosomal or extrachromosomal amplification. (**d**) Cox
proportional hazards regression of NBL tumors from (**c**) on amplification class and clinical
parameters. * *p* < 0.05; ** *p* < 0.01; *** *p* < 0.001.
604

605
Supplementary Figure 7: Survival of Myc family amplified medulloblastoma and
neuroblastoma tumors. (**a**) Survival of 212 MBL tumors with focal amplification stratified by
chromosomal/ecDNA and *MYC* gene family amplification. chr+, chromosomal amplification;
MYC(*N/L*)+/−, *MYC* gene family amplified/nonamplified. (**b**) Cox regression as in
(**Supplementary Figure 6b**), but including an additional covariate for *MYC* family
amplification. (**c**) Survival of 59 NBL tumors with focal amplification, stratified by
chromosomal/ecDNA and *MYCN* amplification. (**d**) Cox regression as in (**Supplementary**
Figure 6d), but including an additional covariate for *MYCN* amplification. * *p* < 0.05; ** *p* <
0.01; *** *p* < 0.001.

615
616
Supplementary Figure 8: Survival of pediatric high-grade glioma tumors w.r.t. ecDNA.
(**a**) Survival of 332 pHGG tumors stratified by chromosomal or extrachromosomal
amplification. (**b**) Cox proportional hazards regression of pHGG tumors from (**a**) on
amplification class and clinical parameters. (**c**) Survival of pHGG tumors as in (**a**), but stratified
additionally on presence/absence of H3K27 alteration. nfa, no focal amplification; chr,
chromosomally amplified; H3K27wt, H3K27 wild-type; H3K27mut, H3K27-altered. (**d**) Cox
regression as in (**b**), but including additional interaction terms stratifying on amplicon class
and H3K27 status. h3k27_x_ecDNA, H3K27 alteration and ecDNA; h3k27_x_amp, H3K27
alteration and focal amplification. * *p* < 0.05; ** *p* < 0.01; *** *p* < 0.001.

627
628
Supplementary Figure 9: ecDNA amplifications detected in primary and recurrent
tumors of rhabdomyosarcoma SJRHB012. (**a**-**b**) A conserved ecDNA sequence containing
amplified *MDM2* which does not show evidence of sequence variation between (**a**) diagnosis
and (**b**) recurrence biosamples of the rhabdomyosarcoma SJRHB012 (modified Jaccard
similarity 0.75). (**c**-**d**) A nonconserved ecDNA sequence in the same tumor. The ecDNA
sequence (**c**) in the primary tumor amplified a 1.5Mbp segment of chr12 including oncogene
CDKN1B. The ecDNA sequence (**d**) in the same tumor at recurrence shared 674kbp of
sequence homology with the primary ecDNA including *BCL2L14*, *LRP6*, *MANSC1*, and
LOH12CR2 but not *CDKN1B* (modified Jaccard similarity 0.21). All visualizations were
generated using the cyclic sequence which explains the greatest proportion of copy number
amplification.
640

METHODS

Pediatric tumor whole genome sequencing (WGS)

Main cohort (PBTA+SJC). Pediatric tumor WGS was identified from two pediatric cancer genomic data repositories, corresponding to 2397 biosamples from 1873 patients in the Pediatric Brain Tumor Atlas (PBTA) and Pediatric Neuro-Oncology Consortium (PNOC); and 1223 biosamples from 1094 patients in the St Jude Cloud (SJC)[12] Pediatric Cancer Genome Project (PCGP; SJC-DS-1001)[70], Clinical Pilot (SJC-DS-1003)[71]; Genomes for Kids (G4K; SJC-DS-1004)[72], Real-Time Clinical Genomics (RTCG; SJC-DS-1007); and Pediatric Brain Tumor Portal (PBTP; SJC-DS-1014)[73]. Inclusion criteria were whole genome sequencing annotated with a solid tumor diagnosis; hematological malignancies, nontumor, and unannotated samples were excluded. Data preprocessing comprised each institution's standard WGS bioinformatics pipelines. Alignments and genomic co-ordinates are w.r.t. human assembly GRCh38 (hg38).

ecDNA detection and classification from bulk WGS

To detect ecDNA, samples in the WGS cohort were analyzed using AmpliconArchitect (AA)[1] v1.2 and AmpliconClassifier (AC)[4] v1.1.2. Briefly, the AmpliconArchitect algorithm was performed as follows. Copy number segmentation and estimation were performed using CNVkit v0.9.6[67]. Segments with copy number (CN) ≥ 4.5 were extracted as "seed" regions using AmpliconSuite-pipeline (April 2020 update)[74]. After confirming that sequencing depth was greater than 10x for all samples (mosdepth v0.3.8[75]), read coverage was downsampled to 10x. Then, for each seed, discordant read pairs indicative of genomic structural rearrangement were identified within and up to 50kbp distal the query region. Genomic segments were defined by genomic breakpoint locations (identified by discordant reads) and by modulations in genomic copy number. A CN-aware breakpoint graph of the amplicon region was constructed using the genome segments and breakpoints, and cyclic and non-cyclic paths are extracted from the graph. Amplicons were classified as ecDNA(+), breakage-fusion-bridge (BFB), complex non-cyclic, linear, or no focal amplification using the heuristic-based companion script AmpliconClassifier. Biosamples with one or more amplicons classified as ecDNA were labelled ecDNA(+). Biosamples without ecDNA but with one or more amplicons classified as BFB, complex non-cyclic or linear were labelled as chromosomally amplified. All other samples were annotated as having no focal amplifications.

All amplifications classified as ecDNA were manually reviewed for possible false positives, marking for reanalysis amplicons satisfying any of the following criteria:
- amplicon has high variability in depth of coverage of mapped reads, indicating a genomic locus of low mappability;
- cyclic subsequences which were assigned CN < 4.

These samples were reanalyzed using the latest AmpliconSuite versions as of Aug. 2024 (AA v1.4.r2, AC v1.2.0). Samples reclassified in this way were BS_2F8PFTW5, BS_XB34VS6P, BS_G6KYSGQF, BS_ GBSSZBMF, and BS_YMYESCY7.

Patient metadata and tumor type annotations

Clinical metadata including sex, age at diagnosis, histology, and tumor history (primary, secondary, etc.) were available from the respective cloud genomics data platforms https://pedcbioportal.kidsfirstdrc.org/ (PBTA) and https://pecan.stjude.cloud/ (SJC), and from

previous peer-reviewed publications[11,54]. Molecular diagnoses were integrated with
histological diagnoses for biosamples included in the Pediatric Brain Tumor Atlas (PBTA)[11] in
the following priority order: molecular subtype, DKFZ v12 methylation classification
(confidence threshold 0.9), DKFZ v11 methylation classification[13] (likewise), harmonized
diagnosis, original histological diagnosis. Diagnoses were subsequently collated and
harmonized between the data sources to annotate the tumor types and subtypes described
herein (**Supplementary Table 11**). Mutation status of high-grade gliomas for *TP53*, *IDH*, and
H3 genes were extracted from diagnosis annotations.

Annotations of tumor purity were available for 2064 biosamples representing 1679 tumors
from the PBTA cohort from a previous publication[11] using the THetA2 software[76]. To annotate
SJC samples, we applied THetA2 to an additional 1231 samples representing 1100 tumors.

Supplementary tumor WGS

Additional MYCN-amplified spinal ependymomas. WGS data from 3 pediatric *MYCN*-amplified
spinal ependymomas was peprocessed, and aligned according to best practices to human
reference GRCh38. Focal amplifications and ecDNA were analyzed as above using
AmpliconArchitect v1.5.r2 and AmpliconClassifier v1.3.3. Results were used to validate
ecDNA amplification of *MYCN* in spinal ependymoma and were excluded from other analyses.

Additional ETMR tumors. WGS data of 38 biosamples from 30 ETMR tumors including 29
samples from a previous publication[27] were uniformly reprocessed and aligned to human
reference GRCh37. Amplicon reconstruction and classification was performed using default
paramaterizations for AmpliconArchitect v1.5.r2 and AmpliconClassifier v1.3.7. To improve
detection sensitivity of low-copy *C19MC* amplifications in 11 samples, AmpliconArchitect was
re-run skipping the default copy number variant detection step and instead specifying the
genomic co-ordinates of suspected *C19MC* amplifications according to the following rules: for
samples where *C19MC* amplification was detected a different sample from the same tumor,
the boundaries of that amplicon were used; and for tumors for which a low-copy gain was
identified (copy number estimate from bulk WGS between 2.5 and 4.5), the boundaries of the
low-copy gain were used. Results were used to validate ecDNA amplification of *C19MC* in
ETMR and excluded from other analyses.

Additional pediatric high-grade gliomas. Previously published WGS data corresponding to 53
pediatric HGG tumors with accompanying clinical metadata including outcomes were
accessed from the archival sequencing data repository[54]. Amplicon detection and
classification was performed as in the main cohort above. Data were included in pHGG
survival analyses and excluded elsewhere.

Additional neuroblastomas. Previously published amplicon annotatations and associated
clinical metadata for 114 neuroblastoma tumors[10] were included in survival analyses of NBL.

Additional medulloblastomas. Previously published amplicon annotatations and associated
clinical metadata for 223 additional medulloblastoma tumors[7] were also included in survival
analyses and excluded elsewhere.

Somatic variant data collection and analysis

Somatic variants. Consensus simple somatic variant data were retrieved from the respective
institutional somatic variant calling and annotation pipelines which passed standard quality
control thresholds[11,12]. Annotations were sourced from Variant Effect Predictor (VEP)[77] and

Ensembl release v105 (CBTN) or v100 (St Jude). Simple somatic variants were defined as
likely pathogenic which satisfied the following criteria:

- affecting a known cancer gene, defined as tumor suppressor and oncogenes included in the COSMIC Cancer Gene Census v101;
- Ensembl consequence (IMPACT) HIGH or MODERATE;
- PolyPhen[78] predicted functionality 'possibly damaging' or 'probably damaging' if available; and
- SIFT[79] predicted functionality 'deleterious' or 'deleterious_low_confidence', if available.

For association testing, likely pathogenic somatic variants were aggregated at the gene level;
ie., biosamples were considered altered at gene G which had any likely pathogenic variant
mapping to G. Association was tested using the χ^2 test for independence with Bonferroni
correction where at least 5 samples were altered at a given gene and at least 5 amplified;
otherwise the association was considered underpowered and therefore not tested.

Germline variants. Annotations of pathogenicity for germline variants of the OpenPBTA
subcohort were retreived from a previous publication[80]. Association testing w.r.t. focal
amplification and ecDNA was performed as described above for somatic variants. Variant
enrichment was plotted using EnhancedVolcano v1.24.0.

Logistic regressions

For all logistic regressions, tumor types were included which had at least 5 cases and at least
1 ecDNA(+) and 1 chromosomally amplified case. Numerical covariates were z-score
normalized according to best practice.

Tumor purity on amplicon class. To determine whether tumor purity influences ecDNA
detection efficiency, we fitted logistic regressions of amplicon class (ecDNA, chromosomal
amplification, or no amplification) on sex, age at diagnosis, and cancer type, including and
excluding tumor purity (as estimated by ThetA2) as an additional covariate. Logistic regression
models were implemented using scikit-learn v1.5.2[81] using the Newton conjugate gradient
solver and no penalty term. Models with and without tumor purity as an additional covariate
were compared by likelihood ratio test.

Tumor mutation burden on amplicon class. Regressions were fitted on age at diagnosis, sex,
source (CBTN or St Jude), tumor mutation burden (TMB), likely pathogenic mutation burden
(LPTMB) and tumor type using statsmodels v0.14.6 and plotted using base matplotlib v3.10.3.

Survival analyses

Patient overall survival data were included in PBTA clinical metadata and provided upon
request from St. Jude. 223 medulloblastoma tumors from the International Cancer Genome
Consortium and analyzed in a previous publication[7] were also included in survival analyses.
St. Jude survival data did not include date of most recent follow-up, so survival data were
censored at the date of data collection. Tumors with linear, complex noncyclic, or breakage-
fusion-bridge amplifications but without ecDNA were classified as chromosomal. Kaplan-
Meier and Cox Proportional Hazards regressions were performed in R 4.5.3 with the survival[82]
v3.8.6 and survminer v0.5.2 packages.

Kaplan-Meier (KM) regressions. Sample was limited to tumor types with at least 5 cases, at
least 1 death and at least 1 ecDNA(+) sample (n = 1892; 225 ecDNA(+), 216 with

chromosomal amplification only, and 1451 unamplified). Differential survival reported for KM
regressions was evaluated by log-rank test.

Cox Proportional Hazards (CPH) regression. Hazard ratios were estimated by CPH regression
parameterized on amplification class, tumor type, sex and age at diagnosis, and evaluated by
log-rank test. Sample was as in KM above but additionally required complete annotations for
sex and age at diagnosis, resulting in 56 exclusions ($n = 1836$). Applicability of the proportional
hazards assumption was validated by likelihood ratio test ($\alpha > 0.1$) implemented in the
`cox.zph` function of the survival package.

Ordinary least-squares linear regression

For regression of amplification status (ecDNA, chromosomal amplification, or no
amplification) on age at diagnosis, ages were binned at 0.1-year resolution and a centered 1-
year rolling average (smoothening) was applied to reduce sampling noise. For tumors with
sampled more than once, the earliest biosample was used for determining amplification status.
Ordinary least-squares linear regression models were then fit independently for each class
using age as the predictor and smoothened class proportion as the response using scikit-
learn[81] v1.5.2. Significance testing was performed using Student's *t*-test implemented in
statsmodels[83] v0.14.2.

Permutation testing of amplification in primary and secondary tumors

To test whether ecDNA (or chromosomal amplification) is more frequent in secondary than
primary tumors, a permutation test was constructed as follows. Let the test statistic $T = f_s -$
f_p, where f_s and f_p are the observed frequencies of ecDNA+ tumors among secondary and
primary tumors respectively. Then, permutations are constructed as follows. For paired
samples, (ie, the same tumor was sampled at diagnosis and again at progression), the
primary/secondary labels are swapped with 50% probability. For unpaired samples, for each
tumor type, primary/secondary labels are shuffled among samples of that tumor type. The
permutation procedure thus samples from a null distribution for which the distribution of
ecDNA across tumor types is unchanged, but without any association with primary/secondary
status. 1000 permutations were performed and a *p*-value calculated according to standard
practice.

Other statistical methods

Statistical test, test statistic and *p*-values are indicated where appropriate in the main text.
Categorical associations were established using the chi-squared test of independence if *n* >
5 for all categories and the Fisher exact test otherwise, both implemented in scipy.stats[84]
v1.10.2. Multiple hypothesis correction was performed where appropriate using the Benjamini-
Hochberg correction implemented in statsmodels[83] v0.14.2 and reported as *q*-values or
adjusted *p*-values. All statistical tests described herein were two-sided unless otherwise
specified. For all tests performed on patient or biosample sets which require an independence
assumption, samples from the same case were deduplicated according to the following priority
order:
• any biosample classified ecDNA(+);
• and if any biosample with focal chromosomal amplification;
• the most recent biosample.

Gene fusions

Fusion genes were identified by adjacency on the ecDNA sequence assemblies. For samples from the PBTA subcohort, fusion gene expression was confirmed from RNA-seq data as described in the source publication[11].

Longitudinal subcohort (Supplementary Figure 9; Supplementary Table 10)

Patient tumors were included in the set of longitudinal cases which satisfied the following criteria:

- *St Jude and PNOC cohorts.* For multiple tumors from the same patient, exactly one is annotated as "diagnosis", and the others are labelled progressive, recurrent, or metastasis;
- *PBTA X00 and X01 cohorts.* Multiple tumors from the same patient for which the difference between the dates of diagnosis of the initial and the most recent biosample exceeds 30 days.

Similarity scores reported between amplicons were calculated using AmpliconClassifier feature_similarity.py v1.1.2. The formal definition and motivation of the similarity score is described previously[15].

Circular sequences illustrated in **Supplementary Figures 4** & **9** reflect the highest-copy cyclic sequence detected using AmpliconArchitect containing the oncogene of interest. Figures were generated using CycleViz v0.2.1.

ACKNOWLEDGMENTS

This work is supported by a generous endowment by the Clayes Foundation to the Research Center for Neuro-Oncology and Genomics within the Rady Children's Institute for Genomic Medicine, a Hannah's Heroes St. Baldrick's Scholar Award (L.C.), the Dragon Master Foundation (L.C.), the Takeda Science Foundation (O.S.C.), funding from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke Institute R01NS132780 (L.C.), R21NS130137 (L.C.) and R21NS120075 (L.C.), the NIH National Cancer Institute P30CA030199 (L.C. and K.Y.), P30CA030199-42-S1 (L.C. and K.Y.), F31CA271777 (O.S.C.) U01CA253547 (J.P.M.), P30CA051008 (J.P.M.), U24CA220341 (J.P.M.), U24CA295532 (J.P.M.), and U24CA264379 (V.B. and J.P.M.), the NIH National Library of Medicine T15LM011271 (O.S.C.), the Japan Society for Promotion of Science (JSPS) 25K23852 (O.S.C.), 24KF0252 (O.S.C.), and Postdoctoral Research Fellowship F24404 (O.S.C. and D.K.), and a Moores Cancer Center Pilot Grant (L.C., V.B., and J.P.M.). This project is also supported by the UCSD/Rady Children's Hospital pediatric hematology oncology fellowship program (S.S.). D.R.G. gratefully acknowledges support by the Clinician Scientist Program of the Mildred Scheel Cancer Career Center HaTriCS[4] at the University Medical Center Hamburg-Eppendorf and the Else Kröner-Fresenius Stiftung (Grant 2025_EKEA.51). This work used Expanse cluster compute services at the San Diego Supercomputer Center through allocation BIO210026 from the Advanced Cyberinfrastructure Coordination Ecosystem: Services & Support (ACCESS) program, which is supported by National Science Foundation grants #2138259, #2138286, #2138307, #2137603, and #2138296. Support through grant P30CA030199 to the Genomics core facility at Sanford Burnham Prebys (NCI designated Cancer Center) is gratefully acknowledged. The content is solely the responsibility of the authors and does not necessarily represent the official views of

the National Institutes of Health. This research was conducted using data made available by The Children's Brain Tumor Network (formerly the Children's Brain Tumor Tissue Consortium). This study makes use of data generated by the St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project and Pediatric Brain Tumor Portal; and the St. Jude Children's Research Hospital Genomes for Kids Study, Clinical Pilot and Real-Time Clinical Genomics projects. We thank J.H. Zhang, C. McLeod, D. Miller, Y. Zhu, D. Higgins and A. Resnick for facilitating data access, A. Calatroni for help with statistical analyses, R.J. Nowling for his open-source implementation of the likelihood ratio test, R. Wachs for figure design assistance, K. Ichimura and F.P.B. Dubois for scientific discussion, and anonymous reviewers for thoughtful and critical feedback.

CONTRIBUTIONS

Conceptualization: S.S., O.S.C., J.P.M., and L.C. Methodology: O.S.C., S.S., J.L., J.P.M., and L.C. Investigation: O.S.C., S.S., E.Y.-C.C., R.K., J.K., A.D., S.Q.W., W.Z., H.H., and J.W. Formal analysis: O.S.C., S.S., E.Y.-C.C., R.K., R.G. Data curation: O.S.C., S.S., E.Y.-C.C., J.L., S.Z.W., E.R.-F., V.B., K.Y., J.P.M., and L.C. Software: O.S.C., S.S., E. Y.-C.C., R.K., J.K., A.D., S.W., W.Z., H.H., M.B., J.L., and Y.Y.L. Resources: J.L., K.O., D.R.G., J.G., D.K., K.Y., J.P.M., and L.C. Validation: Y.Y.L., E.R.-F., A.G.H., K.O., D.R.G., K.W.P., S.Z.W., J.G., and M.K. Visualization: O.S.C., S.S., and E.Y.-C.C. Writing – original draft: O.S.C. and S.S. Writing – review and editing: O.S.C., S.S., E.Y.-C.C., J.L., D.K., V.B., J.P.M., and L.C. Funding acquisition: O.S.C., D.K., V.B., K.Y., J.P.M., and L.C. Supervision: V.B., D.K., M.P., K.Y., J.P.M., and L.C. Project administration: L.C.

DECLARATION OF INTERESTS

The authors declare the following competing interests:

V.B. and J.L. are inventors named in pending patent application no. US 2022/0364182 A1.

V.B. is a co-founder, consultant, SAB member and has equity interest in Boundless Bio, Inc. and Abterra, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

J.L. previously consulted for Boundless Bio, Inc. The terms of this arrangement have been reviewed and approved by the University of California in accordance with its conflict of interest policies.

RESOURCE AVAILABILITY

LEAD CONTACT

Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Lukas Chavez (lchavez@sbpdiscovery.org).

MATERIALS AVAILABILITY

This study did not generate new unique reagents.

DATA AND CODE AVAILABILITY

WGS data from the PBTA and St. Jude datasets are under controlled access as implemented
by the respective organizations but are available from the following sources upon approval
from an institutional data access committee. PBTA patient cohort: Kids First Data Resource
Center (https://kidsfirstdrc.org) via the CAVATICA data portal. Inclusion criteria were patient
solid tumors with WGS in the OpenPBTA, X01, and PNOC datasets. St. Jude patient cohort:
St. Jude Cloud (https://www.stjude.cloud). Inclusion criteria were patient solid tumors with
WGS from the Pediatric Cancer Genome Project (PCGP; SJC-DS-1001), Clinical Pilot (SJC-
DS-1003); Genomes 4 Kids (G4K; SJC-DS-1004), Real-Time Clinical Genomics (RTCG; SJC-
DS-1007); and Pediatric Brain Tumor Portal (PBTP; SJC-DS-1014) datasets as of September
2022. WGS data for additional ETMR and spinal ependymomas will be made available upon
reasonable request.

All source metadata are available in the Supplementary Tables and/or from the cited sources.
Data and derived visualizations describing all amplifications are accessible from the data
portals at https://ccdi-ecdna.org/ and https://ampliconrepository.org/project/PedPanCan.

Source code for the AmpliconArchitect family of software tools is available at:
AmpliconSuite-pipeline: https://github.com/AmpliconSuite/AmpliconSuite-pipeline
consisting of submodules:
•   AmpliconArchitect: https://github.com/AmpliconSuite/AmpliconArchitect
•   AmpliconClassifier: https://github.com/AmpliconSuite/AmpliconClassifier
•   CycleViz: https://github.com/AmpliconSuite/CycleViz/.

Source code for software applets used to run AmpliconSuite-pipeline and other tools on the
DNANexus (St. Jude Cloud) and CAVATICA (PBTA) platforms are available at:
•   https://github.com/chavez-lab/ampliconsuite-dnanexus-applet
•   https://github.com/chavez-lab/ampliconsuite-cwl-workflows
•   https://github.com/jbk708/theta-applet

Source code for variant calling and annotation pipelines are available at:
•   https://github.com/kids-first/kf-somatic-workflow
•   https://github.com/kids-first/kf-annotation-tools

Source code to regenerate analyses and figures is available at
https://github.com/auberginekenobi/pedpancan_ecdna.

REFERENCES

1. Turner, K. M. *et al.* Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity. *Nature* **543**, 122–125 (2017).

2. Lange, J. T. *et al.* The evolutionary dynamics of extrachromosomal DNA in human cancers. *Nat. Genet.* **54**, 1527–1533 (2022).

3. Nathanson, D. A. *et al.* Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA. *Science* **343**, 72 (2014).

4. Gröbner, S. N. *et al.* The landscape of genomic alterations across childhood cancers. *Nature* **555**, 321–327 (2018).

5. Ma, X. *et al.* Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature* **555**, 371–376 (2018).

6. Kim, H. *et al.* Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. *Nat. Genet.* **52**, 891–897 (2020).

7. Chapman, O. S. *et al.* Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. *Nat. Genet.* **55**, 2189–2199 (2023).

8. Bailey, C. *et al.* Origins and impact of extrachromosomal DNA. *Nature* **635**, 193–200 (2024).

9. Koche, R. P. *et al.* Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. *Nat. Genet.* **52**, 29–34 (2020).

10. Rodriguez-Fos, E. *et al.* Mutational topography reflects clinical neuroblastoma heterogeneity. *Cell Genomics* **3**, (2023).

11. Shapiro, J. A. *et al.* OpenPBTA: The Open Pediatric Brain Tumor Atlas. *Cell Genomics* **3**, 100340 (2023).

12. McLeod, C. *et al.* St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. *Cancer Discov.* **11**, 1082–1099 (2021).

13.   Capper, D. *et al.* DNA methylation-based classification of central nervous system

tumours. *Nature* **555**, 469–474 (2018).

14.   Deshpande, V. *et al.* Exploring the landscape of focal amplifications in cancer using

AmpliconArchitect. *Nat. Commun.* **10**, 392 (2019).

15.   Luebeck, J. *et al.* Extrachromosomal DNA in the cancerous transformation of

Barrett's oesophagus. *Nature* **616**, 798–805 (2023).

16.   Tate, J. G. *et al.* COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic*

Acids Res. **47**, D941–D947 (2019).

17.   Liu, Y., Sun, J. & Zhao, M. ONGene: A literature-based database for human

oncogenes. *J. Genet. Genomics Yi Chuan Xue Bao* **44**, 119–121 (2017).

18.   Helmsauer, K. *et al.* Enhancer hijacking determines extrachromosomal circular

MYCN amplicon architecture in neuroblastoma. *Nat. Commun.* **11**, 5823 (2020).

19.   Mure, H. *et al.* Akt2 and Akt3 play a pivotal role in malignant gliomas. *Neuro-Oncol.*

12, 221 (2009).

20.   Turner, K. M. *et al.* Genomically amplified Akt3 activates DNA repair pathway and

promotes glioma progression. *Proc. Natl. Acad. Sci.* **112**, 3421–3426 (2015).

21.   Yang, J. *et al.* TRPS1 drives heterochromatic origin refiring and cancer genome

evolution. *Cell Rep.* **34**, 108814 (2021).

22.   Arakawa, H. Netrin-1 and its receptors in tumorigenesis. *Nat. Rev. Cancer* **4**, 978–987

(2004).

23.   Talbot, J. *et al.* Sonic hedgehog medulloblastomas are dependent on Netrin-1 for

survival. *Nat. Commun.* **16**, 5137 (2025).

24.   Korshunov, A. *et al.* Focal genomic amplification at 19q13.42 comprises a powerful

diagnostic marker for embryonal tumors with ependymoblastic rosettes. *Acta Neuropathol.*

(Berl.) **120**, 253–260 (2010).

25.   Lau, C. C. *et al.* Frequent amplification and rearrangement of chromosomal bands

6p12-p21 and 17p11.2 in osteosarcoma. *Genes. Chromosomes Cancer* **39**, 11–21 (2004).

26.   Mendrzyk, F. *et al.* Isochromosome breakpoints on 17p in medulloblastoma are

flanked by different classes of DNA sequence repeats. *Genes. Chromosomes Cancer* **45**,

401–410 (2006).

27.   Lambo, S. *et al.* The molecular landscape of ETMR at diagnosis and relapse. *Nature*

576, 274–280 (2019).

28.   Mackay, A. *et al.* Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade

and Diffuse Intrinsic Pontine Glioma. *Cancer Cell* **32**, 520-537.e5 (2017).

29.   Diaz, A. K. & Baker, S. J. The Genetic Signatures of Pediatric High-Grade Glioma:

No Longer a One-Act Play. *Semin. Radiat. Oncol.* **24**, 240–247 (2014).

30.   Haase, S. *et al.* Hemispherical Pediatric High-Grade Glioma: Molecular Basis and

Therapeutic Opportunities. *Int. J. Mol. Sci.* **21**, 9654 (2020).

31.   Li, B. K. *et al.* Pineoblastoma segregates into molecular sub-groups with distinct

clinico-pathologic features: a Rare Brain Tumor Consortium registry study. *Acta*

Neuropathol. (Berl.) **139**, 223–241 (2020).

32.   Ghasemi, D. R. *et al.* MYCN amplification drives an aggressive form of spinal

ependymoma. *Acta Neuropathol. (Berl.)* **138**, 1075–1089 (2019).

33.   Raffeld, M. *et al.* High level MYCN amplification and distinct methylation signature

define an aggressive subtype of spinal cord ependymoma. *Acta Neuropathol. Commun.* **8**,

101 (2020).

34.   Potluri, V. R., Helson, L., Ellsworth, R. M., Reid, T. & Gilbert, F. Chromosomal

abnormalities in human retinoblastoma a review. *Cancer* **58**, 663–671 (1986).

35.   Inazawa, J. *et al.* Simultaneous existence of double minute chromosomes and a

homogeneously staining region in a retinoblastoma cell line (Y79) and amplification of N-

myc at HSR. *Cancer Genet. Cytogenet.* **37**, 133–137 (1989).

36.   Mysorekar, V. V., Harish, K., Kilara, N., Subramanian, M. & Giridhar, A. G.

Embryonal rhabdomyosarcoma of the chest wall: a case report and review of the literature.

Indian J. Pathol. Microbiol. **51**, 274–276 (2008).

37.   Gil-Benso, R. *et al.* Cytogenetic and molecular findings related to

rhabdomyosarcoma. An analysis of seven cases. *Cancer Genet. Cytogenet.* **144**, 125–133

(2003).

38.   Hayashi, Y. *et al.* Characterization of an embryonal rhabdomyosarcoma cell line

showing amplification and over-expression of the N-myc oncogene. *Int. J. Cancer* **45**,

705–711 (1990).

39.   Weber-Hall, S. *et al.* Novel formation and amplification of the PAX7-FKHR fusion

gene in a case of alveolar rhabdomyosarcoma. *Genes. Chromosomes Cancer* **17**, 7–13

(1996).

40.   Goldstein, M., Meller, I., Issakov, J. & Orr-Urtreger, A. Novel Genes Implicated in

Embryonal, Alveolar, and Pleomorphic Rhabdomyosarcoma: A Cytogenetic and

Molecular Analysis of Primary Tumors. *Neoplasia* **8**, 332–343 (2006).

41.   Frascella, E. *et al.* Concomitant Amplif ication and Expression of PAX7-FKHR and

MYCN in a Human Rhabdomyosarcoma Cell Line Carrying a Cryptic t(1;13)(p36;q14).

Cancer Genet. Cytogenet. **121**, 139–145 (2000).

42.   Fletcher, J. A., Gebhardt, M. C. & Kozakewich, H. P. Cytogenetic aberrations in

osteosarcomas: Nonrandom deletions, rings, and double-minute chromosomes. *Cancer*

Genet. Cytogenet. **77**, 81–88 (1994).

43.   Gilbert, F., Potluri, V. R., Short, M. P., Kau, C.-L. & Lalatta, F. Retinoblastoma,

chromosome abnormalities and oncogene expression. *Ophthalmic Paediatr. Genet.* **8**, 3–

10 (1987).

44.   Atiye, J. *et al.* Gene amplifications in osteosarcoma—CGH microarray analysis.

Genes. Chromosomes Cancer **42**, 158–163 (2005).

45.   dos Santos Aguiar, S., de Jesus Girotto Zambaldi, L., dos Santos, A. M., Pinto, W. &

Brandalise, S. R. Comparative genomic hybridization analysis of abnormalities in

chromosome 21 in childhood osteosarcoma. *Cancer Genet. Cytogenet.* **175**, 35–40 (2007).

46.   Sayles, L. C. *et al.* Genome-Informed Targeted Therapy for Osteosarcoma. *Cancer*

Discov. **9**, 46–63 (2019).

47.   Yang, L. *et al.* FOXP4-AS1 participates in the development and progression of

osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2. *Biochem.*

Biophys. Res. Commun. **502**, 493–500 (2018).

48.   Both, J. *et al.* Identification of Novel Candidate Oncogenes in Chromosome Region

17p11.2-p12 in Human Osteosarcoma. *PLOS ONE* **7**, e30907 (2012).

49.   Martin, J. W., Squire, J. A. & Zielenska, M. The Genetics of Osteosarcoma. *Sarcoma*

2012, e627254 (2012).

50.   Granberg, I. & Mark, J. The chromosomal aberration of double-minutes in a human

embryonic rhabdomyosarcoma. *Acta Cytol.* **15**, 42–45 (1971).

51.   Steilen-Gimbel, H. *et al.* A novel site of DNA amplification on chromosome 1p32-33

in a rhabdomyosarcoma revealed by comparative genomic hybridization. *Hum. Genet.* **97**,

87–90 (1996).

52.   Williamson, D. *et al.* Relationship between MYCN copy number and expression in

rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. *J.*

Clin. Oncol. **23**, 880–888 (2005).

53.   Sorensen, P. H. B. *et al.* PAX3-FKHR and PAX7-FKHR Gene Fusions Are

Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children's

Oncology Group. *J. Clin. Oncol.* **20**, 2672–2679 (2002).

54.   Dubois, F. P. B. *et al.* Structural variants shape driver combinations and outcomes in

pediatric high-grade glioma. *Nat. Cancer* **3**, 994–1011 (2022).

55.   Schwalbe, E. C. *et al.* Molecular and clinical heterogeneity within MYC-family

amplified medulloblastoma is associated with survival outcomes: A multicenter cohort

study. *Neuro-Oncol.* **27**, 222–236 (2025).

56.   Holdhof, D. *et al.* Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4

mutation are molecularly distinct from SMARCB1-deficient cases. *Acta Neuropathol.*

(Berl.) **141**, 291–301 (2021).

57.   Seong, B. K. A. *et al.* TRIM8 modulates the EWS/FLI oncoprotein to promote

survival in Ewing sarcoma. *Cancer Cell* **39**, 1262 (2021).

58.   Arabzade, A. *et al.* EPEN-04. OVERWHELMING ZFTA-RELA NUCLEAR

LOCALIZATION AS A THERAPEUTIC STRATEGY AGAINST EPENDYMOMA.

Neuro-Oncol. **26**, 0 (2024).

59.   Murray, J. C. *et al.* Detection of Double Minute Chromosomes in a Child with Acute

Lymphoblastic Leukemia. *Cancer Genet. Cytogenet.* **101**, 138–142 (1998).

60.   Zhang, H. *et al.* Characterization and integrated analysis of extrachromosomal DNA

amplification in hematological malignancies. *Neoplasia* **56**, 101025 (2024).

61.   Potocki, L. *et al.* Molecular mechanism for duplication 17p11.2- the homologous

recombination reciprocal of the Smith-Magenis microdeletion. *Nat. Genet.* **24**, 84–87

(2000).

62.   Pentao, L., Wise, C. A., Chinault, A. C., Patel, P. I. & Lupski, J. R. Charcot–Marie–

Tooth type 1A duplication appears to arise from recombination at repeat sequences

flanking the 1.5 Mb monomer unit. *Nat. Genet.* **2**, 292–300 (1992).

63.   Kim, H. *et al.* Mapping extrachromosomal DNA amplifications during cancer

progression. *Nat. Genet.* **56**, 2447–2454 (2024).

64.   Shoshani, O. *et al.* Chromothripsis drives the evolution of gene amplification in

cancer. *Nature* **591**, 137–141 (2021).

65.   Tang, J. *et al.* Enhancing transcription–replication conflict targets ecDNA-positive

cancers. *Nature* **635**, 210–218 (2024).

66.   Mayr, L. *et al.* Effective targeting of PDGFRA-altered high-grade glioma with

avapritinib. *Cancer Cell* **43**, 740-756.e8 (2025).

67.   Gotoh, T. *et al.* Prediction of MYCN Amplification in Neuroblastoma Using Serum

DNA and Real-Time Quantitative Polymerase Chain Reaction. *J. Clin. Oncol.* **23**, 5205–

5210 (2005).

68.   Stepien, N. *et al.* Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-

Amplified Group 3 Medulloblastoma by Droplet Digital PCR. *Cancers* **15**, 2525 (2023).

69.   Madlener, S. *et al.* Clinical applicability of miR517a detection in liquid biopsies of

ETMR patients. *Acta Neuropathol. (Berl.)* **145**, 843–846 (2023).

70.   Downing, J. R. *et al.* The Pediatric Cancer Genome Project. *Nat. Genet.* **44**, 619–622

(2012).

71.   Rusch, M. *et al.* Clinical cancer genomic profiling by three-platform sequencing of

whole genome, whole exome and transcriptome. *Nat. Commun.* **9**, 3962 (2018).

72.   Newman, S. *et al.* Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric

Cancer Revealed by Comprehensive DNA and RNA Sequencing. *Cancer Discov.* **11**,

3008–3027 (2021).

73.   Wu, G. *et al.* Somatic histone H3 alterations in pediatric diffuse intrinsic pontine

gliomas and non-brainstem glioblastomas. *Nat. Genet.* **44**, 251–253 (2012).

74.   AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer

genomes | bioRxiv. https://www.biorxiv.org/content/10.1101/2024.05.06.592768v1.

75.   Pedersen, B. S. & Quinlan, A. R. Mosdepth: quick coverage calculation for genomes

and exomes. *Bioinformatics* **34**, 867–868 (2018).

76.   Oesper, L., Satas, G. & Raphael, B. J. Quantifying tumor heterogeneity in whole-

genome and whole-exome sequencing data. *Bioinformatics* **30**, 3532–3540 (2014).

77.   McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122

(2016).

78.   Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting Functional Effect of Human

Missense Mutations Using PolyPhen-2. *Curr. Protoc. Hum. Genet. Editor. Board*

Jonathan Haines Al **0 7**, Unit7.20 (2013).

79.   Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense

predictions for genomes. *Nat. Protoc.* **11**, 1–9 (2016).

80.   Corbett, R. J. *et al.* Germline pathogenic variation impacts somatic alterations and

patient outcomes in pediatric central nervous system tumors. *Nat. Commun.* **16**, 10282

(2025).

81.   Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.*

12, 2825–2830 (2011).

82.   Therneau, T. A package for survival analysis in R.

83.   Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with

Python. in *Proceedings of the 9th Python in Science Conference* (eds Walt, S. van der &

Millman, J.) 92–96 (2010). doi:10.25080/Majora-92bf1922-011.

84.   Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in

Python. *Nat. Methods* **17**, 261–272 (2020).

1118

1119